Need Help?

463 newly diagnosed patients with Multiple Myeloma underwent whole exome sequencing of tumour and peripheral blood DNA.

463 newly diagnosed patients from the UK Myeloma XI clinical trial (NCT01554852) underwent whole exome sequencing plus targeted capture of the IGH/K/L and MYC loci. 200 ng of DNA were processed using NEBNext DNA library prepartion kit and hybridised to the SureSelect Human All Exon V5 Plus. Four samples were pooled and run on one lane of a HiSeq 2000 using 76-bp paired end reads. DNA from CD138+ selected bone marrow cells (myeloma tumour) as well as peripheral white blood cells were analysed and somatic mutations detected.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001001358 Illumina HiSeq 2000 926
Publications Citations
APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.
Nat Commun 6: 2015 6997
190
The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma.
Clin Cancer Res 22: 2016 5783-5794
57
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma.
Nat Commun 7: 2016 12050
104
Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression.
Nat Commun 7: 2016 13656
22
The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
Haematologica 102: 2017 1617-1625
50
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.
Blood 132: 2018 587-597
257
Microhomology-mediated end joining drives complex rearrangements and overexpression of <i>MYC</i> and <i>PVT1</i> in multiple myeloma.
Haematologica 105: 2020 1055-1066
32
Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns.
Blood Cancer J 10: 2020 70
16
Genomic Classification and Individualized Prognosis in Multiple Myeloma.
J Clin Oncol 42: 2024 1229-1240
15